Radiant Biotherapeutics Announces Poster Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
Article content
TORONTO & PHILADELPHIA — Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver first-in-class transformative therapies for patients facing life-changing disease, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company's Multabody™ platform, a novel approach to stimulating key targets in immunotherapy that have remained out of reach due to toxicity or lack of response.
Article content
Article content
Details on the poster presentation are below:
Article content
Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. Radiant's proprietary Multabody™ platform leverages avidity and multi-specificity, to generate highly efficacious Multabodies with superior potency than other antibody platforms. These powerful Multabodies are a new class of biologics positioned to tackle complex, heterogenous diseases such as cancer, immunology and inflammation, which often have challenging targets and mechanisms. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages standard antibody CMC processes. The groundbreaking efficiency of the platform is driving a novel pipeline of mono-, bi- and tri-specific biologics in multiple therapeutics areas. With offices in Toronto and Philadelphia, Radiant has forged multiple strategic partnerships that validate the Multabody™ platform's broad scientific and clinical utility. For more, visit radiantbio.com.
Article content
Article content
Article content
Contacts
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Cizzle Brands Corporation Releases its Fiscal Q3 2025 Results, Reflecting Net Sales Growth of Over 25% for the Quarter
Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (the 'Company' or 'Cizzle Brands'), has released its financial results for the third quarter of its 2025 fiscal year (three months ended April 30, 2025, referred to herein as ' FQ3 2025 '). This press release features multimedia. View the full release here: Cizzle Brands Corporation released its Fiscal Q3 2025 financial results, demonstrating strong revenue QoQ revenue growth for the quarter along with strong gross margin. Key highlights from Cizzle Brands' FQ3 2025 results include the following (all figures are in Canadian Dollars unless otherwise specified): Net sales of $3,577,113 during FQ3 2025, reflecting 25.24% sequential quarter-over-quarter (' QoQ ') growth from the previous fiscal quarter, bringing total revenues to $9.2 million for the nine months ended April 30, 2025; Gross profit increased by 14% to $1.87 million in FQ3 2025 from $1.64 million in the Company's previous fiscal quarter; Gross margin for the nine months ended April 30, 2025 was 57%; During FQ3 2025, reported U.S. sales grew 73% compared to the previous fiscal quarter, reflecting the Company's increased focus on key markets in the United States; and QoQ increase in Trade Receivables of 28.03% to $3,058,766, reflecting sustained growth of the Company's sales pipeline and a greater amount of Inventory on hand at $3,572,717, or an increase 14.43% over its previous fiscal quarter with no obsolete inventory and no provisions to inventory having been recorded. Please refer to Cizzle Brands' profile on SEDAR+ ( to view the Company's full FQ3 2025 financial statements, as well as its corresponding Management Discussion and Analysis (' MD&A '). Notable developments for Cizzle Brands during its FQ3 2025 period are summarized below. Total count of retailers and other locations carrying CWENCH Hydration™ products across North America and Europe grew to over 3,000 points of distribution; CWENCH Hydration™ became the Official Hydration Partner of USA Hockey, the national governing body of ice hockey in the United States with more than one million players, coaches, officials, and volunteers across the country; CWENCH Hydration™ became the title sponsor of the CWENCH All Canadian Basketball Games and CWENCH All Canadian Volleyball Games; The Company launched CWENCH Hydration™ in a number of key retailers: London Drugs, MacEwen-owned gas stations, Canco Petroleum, Healthy Planet, Farm Boy, and Fortinos. In addition, CWENCH was launched at Metro locations in Ontario and subsequently expanded to Quebec; CWENCH Hydration™ was placed in United Supermarkets (Texas), further adding to the brand's presence in the United States; and The Company graduated to the OTCQB® Venture Market, and the Company's common shares became eligible for electronic deposit at the Depository Trust Company (' DTC ') which simplifies the process of trading CZZLF shares for U.S. investors. Corporate Updates In addition to release of the FQ3 2025 Financial Statements, Cizzle announced today that it has filed with the securities regulatory authorities in Ontario, British Columbia, and Alberta a notice of intention to be qualified to file a short form prospectus under National Instrument 44-101 – Short Form Prospectus Distributions, and an Annual Information Form. The filings qualify Cizzle Brands as a short-form prospectus filer but do not evidence its intent to file a short form prospectus, to enter into any particular financing or transaction or to become a reporting issuer in any jurisdiction. The Company also continues to evaluate a range of strategic alternatives to drive growth and maximize shareholder value as part of its ongoing review. Management is considering options to ensure each business unit is well-positioned, properly resourced, and focused on long-term value creation. Potential actions may include refining the Company's business strategy, focusing on specific products, markets, or partners; asset or business unit transactions; strategic investments; partnerships or joint ventures; or changes to capital structure and allocation. There is no assurance that this process will result in any specific action or transaction, or regarding the timing or outcome if one does occur. Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, 'With the completion of Cizzle Brands' FQ3 2025, it is amazing to consider how much our team accomplished in under one calendar year. While many early-stage sports nutrition companies struggle to drive awareness, our disciplined approach has enabled us to be taken on by several leading Canadian retailers, in addition to Van Houtte Coffee Services Inc., a subsidiary of Keurig Dr Pepper Canada, and leading U.S. organizations such as USA Hockey and LifeTime. These accomplishments have generated quantifiable results, anchored by over CAD $9.2 million in net sales fiscal year-to-date with a gross margin of 57%, and over 3,000 locations carrying CWENCH Hydration products across North America and Europe. This is only the beginning, and on behalf of the Cizzle Brands team we are grateful to all of our investors, partners, and stakeholders who have contributed to the Company's phenomenal performance in its early stages.' About Cizzle Brands Corporation Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 3,000 locations in Canada, the United States, and Europe; and (ii) SPOKEN™ Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle. For more information about Cizzle Brands, please visit: For more information about CWENCH Hydration™, please visit: For more information about SPOKEN™ Nutrition, please visit: On behalf of the Board of Directors of the Company, CIZZLE BRANDS CORPORATION 'John Celenza' John Celenza, Founder, Chairman, and Chief Executive Officer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.
Cision Canada
a day ago
- Cision Canada
Rockwell Automation Helps Customers Unlock the Potential of Their Data with the Launch of OptixEdge
Advanced edge gateway solution transforms the way data is processed, enabling time and cost savings MILWAUKEE, Wis., June 12, 2025 /CNW/ -- Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced the global launch of OptixEdge, an innovative edge gateway solution that revolutionizes data processing for industrial customers. Today's smart machines are generating more data than ever, but according to Rockwell's latest State of Smart Manufacturing Report, only 44% of data is being used effectively. Many companies face challenges that prevent them from utilizing a vast amount of their data, such as network limitations, security concerns, or storage costs. Traditionally, data is sent to distant cloud servers to be processed, but this can be expensive and inefficient. OptixEdge can directly address these issues by processing information where it's created – at the machine, in real time. It connects to the user's control system through Rockwell's FactoryTalk® Optix™ software to collect, analyze, and send data to the cloud, enabling users to monitor and analyze machine or system data from multiple locations. This means faster insights, lower costs, and smarter decision-making. "OptixEdge empowers customers to take control of their data like never before, providing powerful edge computing capabilities with flexibility, security, and ease of use," said Jessica Morell, software product manager at Rockwell Automation. "By processing data at its source, OptixEdge enables customers to unlock valuable insights, improve efficiency, and drive innovation across their operations." Key capabilities of OptixEdge include: Built-in Wizard App: A pre-installed FactoryTalk Optix application simplifies the data collection process and allows for easy configuration using only a web browser, cutting down on engineering time. It also offers the ability for users to build and deploy custom applications, if preferred. Designed for efficiency: Allows lightweight applications to run in tandem with included software. Secure remote access and troubleshooting: Remote assistance is available through FactoryTalk® Remote Access™, allowing remote engineers and maintenance teams to program, configure and troubleshoot systems over a secure VPN connection. Open and flexible: OptixEdge can be utilized in conjunction with a plant or machine's existing Rockwell hardware or third-party graphic terminals and controllers. Cost savings and network performance improvement: OptixEdge offers users the ability to send less data to the cloud, which can help save money on storage and improve network performance. Learn more about Rockwell's innovative OptixEdge solution on Rockwell's website. About Rockwell Automation Rockwell Automation, Inc. (NYSE: ROK) is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 27,000 problem solvers dedicated to our customers in more than 100 countries as of fiscal year end 2024. To learn more about how we are bringing the Connected Enterprise® to life across industrial enterprises, visit
Cision Canada
a day ago
- Cision Canada
Medtronic announces MiniMed as name for planned New Diabetes Company
GALWAY, Ireland, June 12, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world. "Our journey began in 1983, when visionary entrepreneur Alfred E. Mann founded MiniMed and revolutionized diabetes care with many first-of-its-kind innovations that pushed the boundaries of care and helped simplify life with diabetes for countless people around the world," said Que Dallara, current EVP and President of Medtronic Diabetes and Chief Executive Officer designate of MiniMed. "We're thrilled to honor this rich 40-year legacy with a name that carries deep meaning and trust. As we step forward into this new and exciting chapter, we'll focus relentlessly on fulfilling our Mission to make diabetes more predictable so everyone can embrace life to the fullest." Managing diabetes can feel draining and exhausting due to the constant mental and physical demands to keep glucose levels in a healthy range. Every meal and activity requires careful calculation — counting carbs, adjusting insulin, and monitoring levels to prevent dangerous low and high blood sugars that can result in both short- and long-term complications. The company's Mission is inspired by the desire to introduce more stability and predictability with technology that helps push diabetes management into the background. For many employees, the Mission hits close to home—over 70% of those surveyed have a personal connection to diabetes. That includes Key Payton, who has been with the company for over a decade and was diagnosed with type 1 diabetes in 1960. "When I was just three years old, doctors told my parents I likely wouldn't live past 10. But here I am, 65 years later, defying the odds and living my best life. I've experienced firsthand how the company has transformed diabetes care and personally helped me beat those early odds in astounding ways," said Payton. "I'm forever grateful for the hope and support they've given me every day for nearly three decades. Today, I'm a proud user of the MiniMed™ 780G system,** and my Time in Range § has never been better. I'm finally sleeping through the night and worrying less about my diabetes — it's freeing." Based in Northridge, California, the Diabetes business is a passionate team of more than 8,000 employees dedicated to pushing the boundaries of innovation, developing breakthrough technologies that reduce burden, enhance quality of life, improve health outcomes, and redefine standards of care. Medtronic is targeting completion of the planned separation within 18 months of the initial announcement, subject to customary conditions and legal requirements including consultations with works councils and other employee representative bodies. Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to Medtronic's ability to satisfy the necessary conditions to consummate the separation of its Diabetes business on a timely basis or at all, Medtronic's ability to successfully separate its Diabetes business and realize the anticipated benefits from the separation (including consummating the transaction on a basis that is generally tax-free to shareholders), MiniMed's ability to succeed as a standalone publicly traded company, competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of Medtronic. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. While a split-off is Medtronic's current preferred separation structure, a final decision has not been reached at this time. The separation is expected to occur through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof, of the company's remaining shareholding in MiniMed. **MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see § Refers to SmartGuard™ feature. Individual results may vary. Ryan Weispfenning Investor Relations +1-763-505-4626 SOURCE Medtronic plc
